Drugs / RTS,S/AS01E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07036159 | Aug 2025 → Apr 2027 expected | malaria | GlaxoSmithKline | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-06 | GlaxoSmithKline | GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗ |
| 2021-01-27 | GlaxoSmithKline | GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTS,S/AS01E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07036159 ↗ |
| Modality | Vaccine | “RTS,S/AS01E vaccine” NCT07036159 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT07036159 ↗ |